Chinese biotech innovator Jacobio Pharma has struck a global out-licensing deal with pharmaceutical giant AstraZeneca for a promising cancer drug, marking one of the largest cross-border transactions for a Chinese small-molecule oncology candidate currently in clinical trials.
The deal, announced on Monday, centers on a potential $2 billion partnership to tackle KRAS-mutated cancers, long considered one of the most elusive targets in oncology.
Under the terms of the agreement, Hong Kong-listed Jacobio will receive an upfront payment of $100 million. Depending on future development, regulatory, and commercial achievements, the company is eligible to receive up to $1.915 billion in
Continue Reading on China Daily
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.